Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
  • Home
  • Current Issue
  • Early view
  • Review Series
  • Archive
  • About Us
    About Haematologica Editorial Team Our Policies Advertising Rights & Permissions Contact
  • Haematologica Award
    How to participate 2025 Winners
  • Submit a Manuscript
    Author Guidelines Reviewer Guidelines Submit and Track Manuscript Track Manuscript submitted before October 1st, 2025
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Advanced filters
Search the full archive

B10 | HEPTA-REFRACTORY MULTIPLE MYELOMA: BIOLOGY, PROGNOSIS, AND TREATMENT (416 Online Views)

C. Riedhammer1, M. Truger2, H. Lee3, L.B. Leypoldt4|5, M. Meggendorfer2, S. Hutter2, H. Müller2, J. Mersi1, S.K. Kadel1, T. Buchwald1, R. Kosch4, M. Helal6, N. Afrin6, A. Rosenwald7, E. Gerhard-Hartmann7, A. Brioli8|9, J. Krönke8, T. Haferlach2, C. Haferlach2, K.C. Weisel4, P. Neri3, H. Einsele1, K.M. Kortüm1, J.M. Waldschmidt1, N. Bahlis3, N. Weinhold10|11, L. Rasche1|6

1 Department of Internal Medicine 2, University Hospital of Würzburg, Germany
2 MLL Munich Leukemia Laboratory, Germany
3 Arnie Charbonneau Cancer Institute, University of Calgary, Canada
4 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Germany
5 Mildred Scheel Early Career Center, University Medical Center Hamburg-Eppendorf, Germany
6 Mildred Scheel Early Career Center, University Hospital Würzburg, Germany
7 Institute of Pathology, University of Würzburg, Germany
8 Department of Internal Medicine C, University Hospital of Greifswald, Germany
9 Hannover Medical School, Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Germany
10 Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Germany
11 Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center, Germany
Multiple myeloma Hepta-refractory Immunotherapy.

P10 | HIGH ACCURACY OF NEXT-GENERATION FLOW IN PREDICTING MEASURABLE RESIDUAL DISEASE BY NEXT-GENERATION SEQUENCING IN THE 10⁻⁶ RANGE: A PROSPECTIVE COMPARISON WITHIN THE PHASE III EMN24 ISKIA TRIAL (328 Online Views)

M. D'Agostino1, M. Van Duin2, W. Roeloffzen3, M.A. Dimopoulos4|5, L. Rosiñol6, M. Van Der Klift7, J. Martínez-López8, A. Oriol9, E. Katodritou10, K.L. Wu11, P. Rodríguez Otero12, R. Hájek13|14, E. Dama15, D. Oddolo15, G. Gazzera15, E.M. Van Leeuwen-Segarceanu16|17, N.W.C.J. Van De Donk18, S. De Jonge-Peeters19, T.S. Slørdahl20, J. Straub21, M. Westerman22, F. Schjesvold23|24, J. Bladé6, H. Einsele25, M. Boccadoro15, P. Sonneveld2|26, A. Broijl2, F. Gay1

1 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
2 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
3 Department of Hematology, University Medical Center Groningen, The Netherlands
4 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece
5 Department of Medicine, Korea University, Seoul, Korea
6 Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, IDIBAPS and PETHEMA/GEM, Spain
7 Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands
8 Hematology Department, Hospital Universitario de Octubre, Medicine Department Complutense University, imas12, CNIO, Madrid, Spain
9 Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain
10 Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
11 ZNA Cadix, Antwerp, Belgium
12 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
13 Department of Haematooncology, University Hospital Ostrava, Czech Republic
14 Department of Haematooncology, Faculty of Medicine, University of Ostrava, Czech Republic
15 European Myeloma Network, Italy
16 Department of Hematology, St. Antonius Hospital
17 Nieuwegein, The Netherlands
18 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, The Netherlands
19 Department of Hematology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
20 Department of Hematology, St. Olavs University Hospital, Trondheim, Norway
21 Internal Medicine, Hematology Clinic, General University Hospital, Prague, Czech Republic
22 Northwest Clinics, Alkmaar, The Netherlands
23 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Sweden
24 KG Jebsen Center for B cell malignancies, University of Oslo, Sweden
25 Department of Internal Medicine II, University Hospital Würzburg, Germany
26 European Myeloma Network, The Netherlands
Multiple Myeloma Measurable residual disease IsaKRd trial

P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE (322 Online Views)

P. Sonneveld1, P.. Moreau2, H. Einsele3, H. Quach4, P.J. Ho5, M. Beksac6, C. Hulin7, E. Antonioli8, X. Leleu9, S. Mangiacavalli10, A. Perrot11, M. Cavo12, A. Belotti13, A. Broijl1, H. Pei14, A. Sitthi-Amorn14, R.L. Carson14, P. Rodríguez-Otero15, M.A. Dimopoulos16, M. Boccadoro17

1 Erasmus MC Cancer Institute, Rotterdam, The Netherlands
2 University Hospital Hôtel-Dieu, Nantes, France
3 Universitätsklinikum Würzburg, Germany
4 University of Melbourne, Australia
5 Royal Prince Alfred Hospital, Sydney, Australia
6 Ankara University, Turkey
7 Hôpital Haut Lévêque, Pessac, France
8 University of Florence, Italy
9 CHU Poitiers, France
10 University of Pavia, Italy
11 Centre Hospitalier Universitaire de Toulouse, France
12 Bologna University, Italy
13 ASST Spedali Civili di Brescia, Italy
14 Johnson & Johnson, USA
15 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
16 National and Kapodistrian University of Athens, Greece
17 University of Turin, Italy
Minimal residual disease NDMM Therapy

P45 | MODELING DORMANCY IN MULTIPLE MYELOMA: FUNCTIONAL AND TRANSCRIPTOMIC CHARACTERIZATION OF SERUM STARVATION AND CHEMOTHERAPY-INDUCED STATES (265 Online Views)

Z.S. Najafabadi1, N. Afrin2, M. Helal2, H. Fischer1, M. John2, E. Stanojkovska1, J. Mersi1, S. Kadel1, J. Waldschmidt1, M. Kortüm1, K. Kretzschmar2, H. Einsele1, A. Riedel2, L. Rasche1|2

1 Internal Medicine II, Universitätsklinikum Würzburg, Germany
2 Mildred Scheel Early Career Centre for Cancer Research Würzburg, The Julius-Maximilians-Universität Würzburg, Germany
Multiple Myeloma Cancer cell dormancy 3D Model
Loading...
Searching...
1 - 4 of 4 items
Navigate
  • Home
  • Current issue
  • Early view
  • Archive
  • About Haematologica
  • Editorial Team
  • Our policies
  • Contact
For Authors
  • Author Guidelines
  • Submit Manuscript
  • Track Manuscript
For Reviewers
  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
For Advertisers
  • Information For Advertising
Education
  • Review Articles
  • Guidelines Articles
Privacy
  • Cookie Policy
  • Newsletter Privacy Policy
  • Privacy Policy
More
  • Rights & Permissions

  • Web design
  • Development
Copyright © 2026 by the Ferrata Storti Foundation | Web design → | Development →
ISSN 0390-6078 print | ISSN 1592-8721 online